SCHEMBL4586334

SCHEMBL4586334

FC(F)(F)c1ccc2c(c1)sc1ccncc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 5/20 0.51
CHUK O15111 1/20 0.48
EPHX2 P34913 3/20 0.41
SCN4A P35499 1/20 0.41
EGFR P00533 1/20 0.38
HRH4 Q9H3N8 2/20 0.38
DYRK1A Q13627 2/20 0.34
CYP19A1 P11511 1/20 0.34
GSK3A P49840 2/20 0.34
GSK3B P49841 2/20 0.34
CDK5 Q00535 2/20 0.34
PLK4 O00444 1/20 0.34
DYRK3 O43781 1/20 0.34
PRKD3 O94806 1/20 0.34
MAP4K4 O95819 1/20 0.34
CHEK2 O96017 1/20 0.34
FGFR1 P11362 1/20 0.34
CDK2 P24941 1/20 0.34
FLT4 P35916 1/20 0.34
KDR P35968 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25708782 0.84 KIF11 (0.38) KIF11CHUK
SCHEMBL28124653 0.78 GPR3 (0.54) KIF11EPHX2SCN4A
SCHEMBL11884982 0.76 CYP2A6 (0.42) DYRK1AGSK3AGSK3BCDK5PRKD3
SCHEMBL17489631 0.75 SMN1; SMN2 (0.59) LIMK1CYP1A2
SCHEMBL22373856 0.75 ACHE (0.49)
SCHEMBL24056962 0.75 CHUK (0.44) CHUKHRH4CYP1A2CSNK2A1
SCHEMBL20172151 0.75 ALDH1A1 (0.34)
SCHEMBL11884987 0.73 KDM4E (0.40) CHUKDYRK1AGSK3AGSK3BCDK5
SCHEMBL22159418 0.72 MAPT (0.47) CYP19A1LIMK1
SCHEMBL16282365 0.72 KIF11 (0.39) KIF11CHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1954290-A2 TRICYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES Merck & Co., Inc. (US) 2008-08-13 EP disclosed
WO-2007061764-A2 TRICYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES MERCK & CO., INC. (US) 2007-05-31 WO disclosed